Latest news with #Vitalhub
Yahoo
10-08-2025
- Business
- Yahoo
Vitalhub Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Explore Vitalhub's Fair Values from the Community and select yours Vitalhub (TSE:VHI) Second Quarter 2025 Results Key Financial Results Revenue: CA$23.9m (up 47% from 2Q 2024). Net income: CA$1.77m (up from CA$335.1k loss in 2Q 2024). Profit margin: 7.4% (up from net loss in 2Q 2024). EPS: CA$0.032 (up from CA$0.007 loss in 2Q 2024). AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. All figures shown in the chart above are for the trailing 12 month (TTM) period Vitalhub Revenues Beat Expectations, EPS Falls Short Revenue exceeded analyst estimates by 8.1%. Earnings per share (EPS) missed analyst estimates by 25%. Looking ahead, revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Healthcare Services industry in North America. Performance of the market in Canada. The company's shares are up 3.2% from a week ago. Risk Analysis You still need to take note of risks, for example - Vitalhub has 1 warning sign we think you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Business Insider
10-07-2025
- Business
- Business Insider
Raymond James Remains a Buy on Vitalhub (VHI)
In a report released today, Michael W. Freeman from Raymond James maintained a Buy rating on Vitalhub, with a price target of C$14.50. The company's shares closed today at C$12.33. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, W. Freeman is a 3-star analyst with an average return of 5.9% and a 52.63% success rate. W. Freeman covers the Healthcare sector, focusing on stocks such as Bausch Health Companies, NervGen Pharma, and Vitalhub. Vitalhub has an analyst consensus of Strong Buy, with a price target consensus of C$14.10, a 14.36% upside from current levels. In a report released yesterday, Scotiabank also maintained a Buy rating on the stock with a C$15.00 price target. The company has a one-year high of C$12.72 and a one-year low of C$6.74. Currently, Vitalhub has an average volume of 103.6K.
Yahoo
21-06-2025
- Business
- Yahoo
Vitalhub concludes Induction Healthcare acquisition
Canadian software company Vitalhub has announced the completion of its previously announced acquisition of Induction Healthcare Group. The acquisition was finalised through a court-sanctioned scheme of arrangement under Part 26 of the Companies Act 2006. Vitalhub consented to the acquisition terms in April, agreeing to a cash purchase that values Induction Healthcare at approximately £9.7m ($13.06m). Induction is known for its primary products, Zesty and Attend Anywhere, both of which are designed to enhance the patient journey and streamline hospital operations. Zesty serves as a patient engagement platform, while Attend Anywhere facilitates secure video consultations for healthcare organisations. For the six months ending on 30 September 2024, Induction reported revenues of £5.4m, with a gross margin of 78.2% and an adjusted EBITDA loss of £0.9m. Zesty generated £2m and Attend Anywhere reported £3.2m in revenues, with a small portion from discontinued operations. During acquisition, Zesty's annual recurring revenue stood at £2.2m, and Attend Anywhere's virtual care recurring revenue was at £4.6m. VitalHub CEO Dan Matlow said: 'We see the Induction product set, in particular the Zesty platform, as highly complementary to our current suite of solutions. 'We believe our expanded end-to-end offering will enhance the value to our healthcare partners, improving the end-user experience and patient outcomes.' Vitalhub's acquisition of Induction for £0.10 per share aligns with its growth strategy, which includes both organic development and an aggressive approach to mergers and acquisitions. The company's product suite serves more than 1,000 clients across the UK, Canada, and other regions, with a workforce of over 500 employees worldwide. Induction's software solutions are designed to offer healthcare providers and administrators the ability to deliver care both remotely and face-to-face. This acquisition not only broadens Vitalhub's offerings but also aims to give communities more flexibility and ease of access to healthcare services. "Vitalhub concludes Induction Healthcare acquisition" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
